Brief: Targovax Oncos-102 Achieves 25.0 Months Median Overall Survival In First Line Mesothelioma

Circio Holding ASA

20/12/2021 06:53

Dec 20 (Reuters) - Targovax ASA  TRVX.OL :
    * ONCOS-102 ACHIEVES 25.0 MONTHS MEDIAN OVERALL SURVIVAL IN FIRST LINE MESOTHELIOMA
    * MEDIAN OVERALL SURVIVAL (MOS) WAS 25.0 MONTHS IN FIRST-LINE GROUP OF PATIENTS TREATED WITH
ONCOS-102 PLUS CHEMOTHERAPY, COMPARED WITH 13.5 MONTHS MOS FOR CHEMOTHERAPY-ONLY CONTROL GROUP

Source text for Eikon:  ID:nObiC6ypQa 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))